Global Blood Therapeutics Inc. - Special Call
Conference Call Global Blood Therapeutics Inc
Global Blood Therapeutics Inc Conference call will be held on Dec 11, 2017. During the earnings conference call's session Global Blood Therapeutics Inc will provide updated information and financial status.
Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period
In order to join the earnings online meeting, contact Global Blood Therapeutics Inc for the information on connecting using web conferencing or bridge number and PIN code
Schedule an online meeting with QCONF conference service and get free conference bridge.
We are a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. Our lead product candidate is GBT440, an oral, once-daily therapy that modulates hemoglobin's affinity for oxygen, which we believe inhibits hemoglobin polymerization in sickle cell disease, or SCD, and improves hypoxemia in idiopathic pulmonary fibrosis, or IPF. We are developing GBT440 for SCD. We are currently evaluating GBT440 in SCD in a Phase 3 clinical trial of GBT440 in adult and adolescent patients with SCD. In addition, we are evaluating the safety and pharmacokinetics of single and multiple doses of GBT440 in a Phase 2a clinical trial of adolescent patients with SCD.Read more Conference Call